In 2024, SAMHSA made the most significant update to Opioid Treatment Program regulations in over two decades — this page explains exactly what changed and what it means for you.
The old system
Previously, patients typically needed to demonstrate sustained stability over an extended period — sometimes many months — through daily supervised dosing before earning any take-home doses, with a rigid “stable” versus “less stable” classification system determining how many days of take-home medication someone could receive.
What changed
- Effective April 2, 2024 (compliance required by facilities by October 2, 2024), SAMHSA’s final rule made permanent flexibilities originally introduced during the COVID-19 pandemic, and expanded them further
- Faster access to take-home doses: patients can now receive up to 7 days of take-home medication within their first 14 days of treatment in many cases — a dramatic change from the old system’s much longer qualification period
- Removed rigid length-of-treatment requirements for determining take-home eligibility, giving clinicians more ability to base decisions on individualized assessment of a specific patient rather than a fixed timeline
- Higher initial methadone dosing allowed (up from a 30mg to a 50mg cap for the first dose), particularly relevant for patients with high opioid tolerance, including from fentanyl exposure
- Removed the one-year documented history requirement for OUD treatment eligibility
An important caveat: state variation
Not every state adopted every flexibility at the same pace — several states did not immediately concur with all aspects of the federal flexibilities as of the rule’s rollout. If your specific OTP seems more restrictive than what this page describes, it may reflect your state’s specific implementation, not an error at your clinic — worth asking directly about your state’s current policy.
Why this change matters
Daily clinic visits are one of the most commonly cited barriers to starting or staying in methadone treatment — for people balancing work, childcare, or long travel distances to a clinic, this change substantially reduces that burden without changing the medication itself.
Medically reviewed by [pending]. Sources: SAMHSA 2024 Final Rule (Federal Register, February 2, 2024); 42 CFR Part 8 as amended.